News | June 21, 2021
Zydus and Bayer announce extension of their JV
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access
The study was conducted in patients with mild to moderate COVID-19
The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailment
Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
Subscribe To Our Newsletter & Stay Updated
